International, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS)

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >International, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS)

【24h】

International, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS)

机译：国际，第3阶段试验：Balixafortide（CXCR4拮抗剂）加二林蛋白与Eribulin单独服用Her2阴性，局部复发或转移性乳腺癌（堡垒）国际，第3阶段试验：Balixafortide（A CXCR4拮抗剂）加二林蛋白与二林林单独相反 HER2阴性，局部复发或转移性乳腺癌（堡垒）的患者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共4页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
专利

1. International, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：国际，第3阶段试验：Balixafortide（CXCR4拮抗剂）加二林蛋白与Eribulin单独服用Her2阴性，局部复发或转移性乳腺癌（堡垒）国际，第3阶段试验：Balixafortide（A CXCR4拮抗剂）加二林蛋白与二林林单独相反 HER2阴性，局部复发或转移性乳腺癌（堡垒）的患者
2. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial [J] . Pernas Sonia, Martin Miguel, Kaufman Peter A., The lancet oncology . 2018,第6期

机译：Balixafortide加二林蛋白在Her2阴性转移性乳腺癌中：1期，单臂，剂量升级试验
3. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial [J] . Pernas Sonia, Martin Miguel, Kaufman Peter A., The lancet oncology . 2018,第6期

机译：Balixafortide加二林蛋白在Her2阴性转移性乳腺癌中：1期，单臂，剂量升级试验
4. Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer [C] . Author(s): Markus F. Renschler Pharmacyclics Inc. Sunnyvale CA USA, Alan R. Yuen Stanford Univ. Palo Alto CA USA, Timothy J. Panella Thompson Cancer Survival Ctr. Knoxville TN USA, Optical Methods for Tumor Treatment and Detections: Mechanisms and Techniques in Photodynamic Therapy VII . 1998

机译：卟啉（Lu-Tex）对局部复发性乳腺癌患者的光动力治疗试验
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Quality of life outcomes including neuropathy-associated scale from a phase II multicenter randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) [O] . Ji-Yeon Kim, Seri Park, Seock-Ah Im, 2019

机译：生活质量的结果包括II期多中心埃瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的神经病相关评分的随机临床试验：韩国癌症研究小组试验（KCSG BR13-11）
7. Ramucirumab with eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy: A multicenter, randomized, phase II study [O] . Ademuyiwa Foluso, et al 2016

机译：雷米库单抗联合艾瑞布林与艾瑞布林治疗以前接受蒽环类和紫杉烷治疗的局部复发或转移性乳腺癌：一项多中心，随机，II期研究

著录项

相似文献

相关主题

期刊订阅